An Androgen Receptor Inhibitor for Treating Advanced Prostate Cancer
Enzalutamide (XTANDI®) is a prescription medicine newly approved to treat men with castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone) that has spread to other parts of the body and who have received treatment with docetaxel. XTANDI is taken orally - four capusles once a day.
Your physician will determine if you are an appropriate candidate for this treatment option. If you are to start XTANDI, you will work closely with your healthcare team who will closely monitor your progress as well as help you deal with any side effects of the treatment.
XTANDI is an adrogen receptor inhibitor that, in preclinical studies, has been shown to work within prostate cancer cells to:
- Induce cell death
- Decrease proliferation
- Decrease tumor volume
A large scale clinical trial was conducted to evaluate effectiveness and safety of the XTANDI capsule that included 1,199 men. 800 of the men were given XTANDI and 399 were given a placebo (capsule containing no active medication). The main objective of the study was to measure overall survival.
Results of this clinical study showed the following:
- Men taking XTANDI lived longer than men taking placebo
- 18.4 months was the median overall survival of men taking XTANDI vs. 13.6 months with the placebo
Important information about XTANDI clinical studies and safety information including drug interactions and side effects can be found here.